Clinical Trial Detail

NCT ID NCT03953898
Title Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Olaparib

Age Groups: adult senior

Additional content available in CKB BOOST